(firstQuint)A Study of FOLFOXIRI Plus Cetuximab vs.

 FOLFOXIRI Plus Bevacizumab.

 This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.

 In this study the investigators employed deepness of response as a primary endpoint.

.

 A Study of FOLFOXIRI Plus Cetuximab vs.

 FOLFOXIRI Plus Bevacizumab@highlight

This study is to verify the advantage of FOLFOXIRI plus cetuximab over FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors.

